Outcomes of interest included change in nutrition knowledge, attitudes, behavior, or weight and/or body composition.
Secondary endpoints included change in crestal bone level between baseline and 12 months, implant survival and success rates, and patient satisfaction.
Other secondary parameters included change from baseline in best-corrected visual acuity as measured by ETDRS charts and in macular thickness as measured by spectral domain OCT.
Our measures of sensitivity included change in coefficient values, prediction success, and the area of mapped habitats following the systematic introduction of geographic error and bias in occurrence data, thematic misclassification of resource maps, and variation in model design.
Analyses included change from baseline in mean monthly migraine days (MMDs) and achievement of ≥50% reduction from baseline in MMDs, assessed over weeks 13 24 (months 4, 5, and 6).
The majority had attended programmes that included change management skills.
Primary evaluation measures included change in weight, CD4 count, viral load, and mortality.
Efficacy endpoints included change in respiratory symptoms, urine output and weight.
Secondary measures included change in 24-h blood pressure and glomerular filtration rate (GFR).
The most frequently reported cough triggers included change of temperature (57%), talking (49%) and odours (45%).
Tertiary outcomes included change in body mass index and current tobacco use (smoked or chewable) status.
